Resona Asset Management Co. Ltd. Purchases Shares of 325,921 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Resona Asset Management Co. Ltd. acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, Holdings Channel reports. The fund acquired 325,921 shares of the company’s stock, valued at approximately $7,211,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in TEVA. Stifel Financial Corp boosted its stake in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after acquiring an additional 33,277 shares during the period. Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $4,966,000. Asset Management One Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after acquiring an additional 58,413 shares during the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $3,340,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.8 %

Shares of TEVA opened at $13.91 on Tuesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The stock has a market cap of $15.77 billion, a PE ratio of -9.59, a P/E/G ratio of 1.44 and a beta of 0.72. The stock’s 50-day moving average is $16.36 and its two-hundred day moving average is $17.99.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TEVA shares. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.